Previous studies have demonstrated that PARP inhibitors can effectively destroy tumors with defective BRCA genes as well as those in testicular cancer cell lines with low homologous recombination proficiency according to the concept of synthetic lethality. Here, PARP1 is linked to testicular cancer.